Concepedia

Keith Usiskin

KU

Statistics

Publications

30

Citations

8K

H-Index

26

Active since

2012

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Western University

Bristol-Myers Squibb (United States)

University of California San Diego

Keith Usiskin is an author at Janssen (United States) specializing in pharmacotherapy, medicine, and clinical pharmacology.

Publications per year

2012–2022

30

Publications

30

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Céline Bellenguez, Fahri Küçükali, Iris E. Jansen et al. · Nature Genetics · 2022 · 2.5K citations · Full text

, , +17

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim et al. · Diabetes Obesity and Metabolism · 2012 · 611 citations · Full text

, , +17

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn, Brian G. Feagan, Geert D’Haens et al. · New England Journal of Medicine · 2021 · 532 citations · Full text

, , +14

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

J.‐F. Yale, George L. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2013 · 486 citations · Full text

, , +17

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Nelson B. Watts, John P. Bilezikian, Keith Usiskin et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 449 citations · Full text

, , +16

1–5 of 30